SCHEMBL2978207

SCHEMBL2978207

COc1cc2c(cc1OC)CN(c1ncc(C(=O)NO)cn1)CC2

nearest known ligand 0.70

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 6/20 0.70
MAPT P10636 1/20 0.50
HDAC1 Q13547 5/20 0.47
EHMT2 Q96KQ7 1/20 0.47
ADAMTS4 O75173 2/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
HDAC3 O15379 2/20 0.46
HDAC2 Q92769 2/20 0.46
MAOB P27338 3/20 0.45
MAPK1 P28482 1/20 0.44
NPC1 O15118 1/20 0.44
LMNA P02545 1/20 0.44
RAB9A P51151 1/20 0.44
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2970425 0.85 HDAC6 (0.54) HDAC6HDAC1HDAC3HDAC2
SCHEMBL2963925 0.85 HDAC6 (0.54) HDAC6MAPTHDAC1ADAMTS4MEN1
SCHEMBL2278231 0.83 HDAC6 (1.00) HDAC6
SCHEMBL30309503 0.81 HDAC6 (0.78) HDAC6
SCHEMBL28975357 0.80 HDAC6 (0.79) HDAC6
SCHEMBL2972419 0.75 NMT1 (0.54) HDAC6MAPTMEN1KMT2AMAOB
SCHEMBL9008431 0.74 MAOB (0.60) MAPTADAMTS4MEN1KMT2AMAOB
SCHEMBL2969659 0.74 KMT2A (0.53) HDAC6MAPTMEN1KMT2AMAOB
SCHEMBL1618849 0.71 HDAC3 (0.69) HDAC6MAPTHDAC1HDAC3HDAC2
SCHEMBL2975835 0.71 BAZ2B (0.58) HDAC6HDAC1HDAC3HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2008530136-A 2008-08-07 JP claimed
EP-1851219-A1 FUSED HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF HISTONE DEACETYLASE Miikana Therapeutics, Inc. (US) 2007-11-07 EP claimed
US-20060199829-A1 Inhibitors of histone deacetylase MIIKANA THERAPEUTICS, INC. 2006-09-07 US claimed
WO-2006088949-A1 FUSED HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF HISTONE DEACETYLASE MIIKANA THERAPEUTICS, INC. (US) 2006-08-24 WO claimed
US-7772245-B2 Inhibitors of histone deacetylase MIIKANA THERAPEUTICS, INC. (US) 2010-08-10 US disclosed
US-7772245-B2 Inhibitors of histone deacetylase MIIKANA THERAPEUTICS, INC. (US) 2010-08-10 US disclosed
US-20060199829-A1 Inhibitors of histone deacetylase MIIKANA THERAPEUTICS, INC. 2006-09-07 US disclosed
WO-2006088949-A1 FUSED HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF HISTONE DEACETYLASE MIIKANA THERAPEUTICS, INC. (US) 2006-08-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060199829-A1 Inhibitors of histone deacetylase HDAC1, HDAC2, HDAC11 HDAC6 11/4885MAPT 2758/4885HDAC1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.